Cellceutix Provides Insights to Its Four Clinical Trials for the Treatment of ABSSSI (Completed Phase 2), Anti-Cancer (Phase 1), Psoriasis (Phase 2), and Oral Mucositis in Head and Neck Cancer Patients (Phase 2)
August 07, 2015 09:31 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - August 07, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Commences Phase 2 Trial of Prurisol as New Treatment for Psoriasis
August 06, 2015 08:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - August 06, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
August 03, 2015 09:14 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - August 03, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
July 20, 2015 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - July 20, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...
Cellceutix's Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
July 15, 2015 13:14 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - July 15, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...
Cellceutix Provides Update on Uplist Application
June 08, 2015 07:58 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - June 08, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...
Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia
June 03, 2015 09:27 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - June 03, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...
Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
June 01, 2015 08:10 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - June 01, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...
Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors at American Society of Clinical Oncology (ASCO) Annual Meeting
May 28, 2015 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - May 28, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...
Enrollment Begins in Cellceutix Phase 2 Trial of Brilacidin-OM to Prevent Oral Mucositis in Patients Undergoing Chemoradiation
May 26, 2015 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - May 26, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...